Overview

Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7

Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
0
Participant gender:
All
Summary
This Phase 2 study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mirati Therapeutics Inc.
Treatments:
Adagrasib
Pembrolizumab
Criteria
Inclusion Criteria:

- Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with KRAS G12C
mutation and known PD-L1 Tumor Proportion Score (TPS) score.

- Unresectable or metastatic disease.

Exclusion Criteria:

- Prior systemic treatment for locally advanced or metastatic NSCLC including
chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C
mutation (e.g., AMG 510).

- Active brain metastases.